FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030910147> ?p ?o ?g. }

• W2030910147 endingPage "272" @default.
• W2030910147 startingPage "S" @default.
• W2030910147 abstract "Background: This study aimed to assess the comparative efficacy and safety of biologics in adult patients with moderately to severely active UC, stratified by prior exposure to antiTNF inhibitors. Methods: MEDLINE, Embase, The Cochrane Library, and ClinicalTrials.gov were systematically searched using a predefined search strategy, without language restrictions, for studies of approved biologics for UC (adalimumab, golimumab, infliximab, vedolizumab) published before February 2014. Two reviewers independently assessed studies for inclusion using a 2-step process; data on study design, patient characteristics, and outcomes were extracted from 8 RCTs (GEMINI I, ULTRA-1, ULTRA-2, ACT-1, ACT-2, PURSUIT-SC, PURSUIT-M, Suzuki et al. [2014] J Gasteronenterol, 49(2):283-94) that met the inclusion criteria and were suitable for network meta-analysis (NMA). The NMA was conducted for key endpoints at induction and maintenance, where data were available, in R and OpenBUGS using Bayesian fixed effects mixed treatment comparisons. Assumptions were made to account for differences in maintenance study design. Results: Seven studies were included in the analysis of induction treatment for anti-TNF-naive patients. All biologics were more effective than placebo in terms of response, remission, and mucosal healing, but rankograms suggested no significant differences between the included biologics. These results were consistent with recent reports (Danese et al. [2014] Ann Intern Med, 160(10):704-11). Five studies were included in the analysis of maintenance treatment for anti-TNF-naive patients. Vedolizumab every 8 weeks (Q8W) resulted in improved results versus comparators for all outcomes at week 52 and was associated with a significantly higher rate of durable clinical response than all comparators (Table 1). In patients who had previously received anti-TNFs, only vedolizumab and adalimumab could be compared. At induction, no significant differences in efficacy were observed between the 2 biologics. During maintenance treatment, vedolizumab resulted in improved rates of durable response and remission and significantly improved rates of mucosal healing compared with adalimumab (Table 1). Conclusion: This study adds to the current understanding of the comparative efficacy and safety of biologic treatment for UC, encompassing outcomes and populations not included in previous studies. All biologic treatments are effective in the treatment of UC, with vedolizumab demonstrating benefits compared with all comparators irrespective of prior anti-TNF exposure in the maintenance setting." @default.
• W2030910147 created "2016-06-24" @default.
• W2030910147 creator A5014132939 @default.
• W2030910147 creator A5044402036 @default.
• W2030910147 creator A5050304186 @default.
• W2030910147 creator A5063018115 @default.
• W2030910147 creator A5063732780 @default.
• W2030910147 creator A5072308088 @default.
• W2030910147 creator A5079729596 @default.
• W2030910147 date "2015-04-01" @default.
• W2030910147 modified "2023-09-25" @default.
• W2030910147 title "Sa1258 Comparison of Real-World Outcomes of Adalimumab (ADA) and Infliximab (IFX) for Patients With Ulcerative Colitis (UC) in the United States" @default.
• W2030910147 doi "https://doi.org/10.1016/s0016-5085(15)30898-2" @default.
• W2030910147 hasPublicationYear "2015" @default.
• W2030910147 type Work @default.
• W2030910147 sameAs 2030910147 @default.
• W2030910147 citedByCount "2" @default.
• W2030910147 countsByYear W20309101472016 @default.
• W2030910147 countsByYear W20309101472019 @default.
• W2030910147 crossrefType "journal-article" @default.
• W2030910147 hasAuthorship W2030910147A5014132939 @default.
• W2030910147 hasAuthorship W2030910147A5044402036 @default.
• W2030910147 hasAuthorship W2030910147A5050304186 @default.
• W2030910147 hasAuthorship W2030910147A5063018115 @default.
• W2030910147 hasAuthorship W2030910147A5063732780 @default.
• W2030910147 hasAuthorship W2030910147A5072308088 @default.
• W2030910147 hasAuthorship W2030910147A5079729596 @default.
• W2030910147 hasConcept C126322002 @default.
• W2030910147 hasConcept C17991360 @default.
• W2030910147 hasConcept C2777138892 @default.
• W2030910147 hasConcept C2779134260 @default.
• W2030910147 hasConcept C2780132546 @default.
• W2030910147 hasConcept C2780479503 @default.
• W2030910147 hasConcept C71924100 @default.
• W2030910147 hasConcept C90924648 @default.
• W2030910147 hasConceptScore W2030910147C126322002 @default.
• W2030910147 hasConceptScore W2030910147C17991360 @default.
• W2030910147 hasConceptScore W2030910147C2777138892 @default.
• W2030910147 hasConceptScore W2030910147C2779134260 @default.
• W2030910147 hasConceptScore W2030910147C2780132546 @default.
• W2030910147 hasConceptScore W2030910147C2780479503 @default.
• W2030910147 hasConceptScore W2030910147C71924100 @default.
• W2030910147 hasConceptScore W2030910147C90924648 @default.
• W2030910147 hasIssue "4" @default.
• W2030910147 hasLocation W20309101471 @default.
• W2030910147 hasOpenAccess W2030910147 @default.
• W2030910147 hasPrimaryLocation W20309101471 @default.
• W2030910147 hasRelatedWork W1946705845 @default.
• W2030910147 hasRelatedWork W1968760412 @default.
• W2030910147 hasRelatedWork W2011851409 @default.
• W2030910147 hasRelatedWork W2020873782 @default.
• W2030910147 hasRelatedWork W2402302369 @default.
• W2030910147 hasRelatedWork W2594662902 @default.
• W2030910147 hasRelatedWork W2789863584 @default.
• W2030910147 hasRelatedWork W3137991202 @default.
• W2030910147 hasRelatedWork W3147486766 @default.
• W2030910147 hasRelatedWork W1540884887 @default.
• W2030910147 hasVolume "148" @default.
• W2030910147 isParatext "false" @default.
• W2030910147 isRetracted "false" @default.
• W2030910147 magId "2030910147" @default.
• W2030910147 workType "article" @default.